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Objective: FTY720, an immunomodulator derived from sphingosine-1-phosphate, 
has recently demonstrated its immunomodulatory, anti-inflammatory, anti-oxidant, 
anti-apoptotic and anti-inflammatory properties. Furthermore, FTY720 might be a key 
pharmacological target for preconditioning. In this preclinical model, we have investigated 
the effects of FTY720 on myocardium during reperfusion in an experimental model of 
cardioplegic arrest (CPA) and cardiopulmonary bypass.
Methods: 30 Sprague–Dawley rats (300–350 g) were randomized into two groups: 
Group-A, treated with FTY720 1 mg/kg via intravenous cannulation, and Group-B, as 
control. After 15 min of treatment, rats underwent CPA for 30 min followed by initiation 
of extracorporeal life support for 2 h. Support weaning was done, and blood and 
myocardial tissues were collected for analysis. Hemodynamic parameters, inflammatory 
mediators, nitro-oxidative stress, neutrophil infiltration, immunoblotting analysis, and 
immunohistochemical staining were analyzed and compared between groups.
Results: FTY720 treatment activated the Akt/Erk1/2 signaling pathways, reduced 
the level of inflammatory mediators, activated antiapoptotic proteins, and inhibited 
proapoptotic proteins, leading to reduced nitro-oxidative stress and cardiomyocyte 
apoptosis. Moreover, significant preservation of high-energy phosphates were observed 
in the FTY720-treated group. This resulted in improved recovery of left ventricular systolic 
and diastolic functions.
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INTRODUCTION
Fingolimod (FTY720), an immunomodulator drug targeting the 
sphingosine-1-phosphate (S1P) receptor with anti-inflammatory 
properties, is a widely recommended drug for relapsing-remitting 
multiple sclerosis (Pelletier and Hafler, 2012; Ayzenberg et al., 
2016). It has been demonstrated to protect the heart against 
myocardial injury in various animal models (Kennedy et al., 2009; 
Santos-Gallego et al., 2016; Ahmed, 2017; Ahmed et al., 2017). 
Mainly, these protective effects were attributed to its anti-oxidant, 
anti-apoptotic and anti-inflammatory properties (Santos-Gallego 
et al., 2016; Ahmed et al., 2017). Oxidative stress and inflammatory 
mediators are known to be associated with ischemia–reperfusion 
(I/R) injury and most probably are responsible for myocardial 
injury (Penna et al., 2009; Sanada et al., 2011)
Furthermore, both inflammatory mediators and oxidative 
stress trigger the opening of the mitochondrial permeability 
transition pore (mPTP), which happens in reperfusion injury 
(Venditti et al., 2001). The mPTP opening causes myocardial 
damage by initiating the uncoupling of mitochondria, leading to 
hydrolysis instead of ATP synthesis.
Therapeutic targets that play a role in the inhibition of mPTP 
opening are considered cardioprotective, and as per literature, 
cardiac functional recovery can be estimated by a reduction in 
mPTP opening (Griffiths and Halestrap, 1995; Javadov et al., 
2017). Recent studies have demonstrated that along with other 
inflammatory cascades and oxidative stress, nitroxidative stress 
also plays an important role in I/R-induced myocardial tissue 
injury (Plotnikov et al., 2007). Excessive production of nitric 
oxide (NO) from NOS and its highly reactive products such 
Conclusion: The cardioprotective mechanism in CPA is associated with activation of 
prosurvival cell signaling pathways that prevents myocardial damage. FTY720 preserves 
high-energy phosphates attenuates myocardial inflammation and oxidative stress, and 
improves cardiac function.
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as peroxynitrite and superoxide has been reported to activate 
several apoptotic pathways leading to apoptotic cell death (Gielis 
et al., 2017). Furthermore, FTY720 also play important role in 
activating multiple signaling pathways including Akt/Erk1/2 
and Pak1 to reduce IRI, cardiac arrhythmias and ventricular 
hypertrophy (Wang et al., 2018; Wang et al., 2019).
Although there is evidence that FTY720 contributes to 
cardioprotection against I/R injury, its protective role in association 
with cardioplegia during cardiac surgery has not been studied yet.
The S1P receptor agonist (FTY720) might act as a potential 
pharmacological agent for cardioprotection in cardioplegia; 
therefore, the aim of this study was to assess the cardioprotective 
effects of S1P receptor activation by FTY720 in the clinical setting 
of cardioplegic arrest (CPA) in an experimental rat model. To 
understand the cardioprotective role of FTY720, we investigated 
inflammatory mediators and oxidative stress in addition to 
functional hemodynamic parameters.
METHODS
This study was conducted in the Division of Cardiac Surgery and 
Translational Surgery Lab, University of Verona Medical School, 
Verona, Italy. The study was directed in compliance with best 
research practice and according to the Declaration of Helsinki 
principles. The protocol was approved by the local Joint Ethical 
Committee for University of Verona and Hospitals (Verona and 
Rovigo), Italy (BBCCH1337).
Animals
After institutional animal care committee approval, 30 male 
Sprague–Dawley rats (300–350 g) were obtained from Harlan 
Laboratories (Udine, Italy) and fed on standard rat chow, which 
they had access ad libitum. The rats were housed at a density of 
3–4 per cage and maintained on a 12-h light/dark cycle at 21°C.
Rats were secured in a supine position on a heating board to 
maintain rectal temperature at 37°C during the surgical procedure 
before the initiation of CPA. Rats were anesthetized (sodium 
pentobarbital, 30 mg/kg intraperitoneally) and intubated using 
oropharynx with a 14-gauge polyethylene tube. Mechanical 
ventilation was done with a rodent ventilator (Harvard Apparatus 
Inc., Holliston, MA). The tidal volume was 6 ml/kg, and the 
respiratory rate was 50–60 breaths/min with an air–oxygen 
mixture (inspired oxygen fraction = 0.5) (Rungatscher et al., 
2015). The left femoral artery was cannulated with a heparinized 
24-gauge Teflon catheter to monitor the systemic arterial pressure, 
and central cannulation was performed, as previously described 
(Rungatscher et al., 2013). Briefly, after complete sternotomy, a 
venous cannula (a modified 4-hole 16-gauge Angiocath catheter) 
was introduced into the right atrium with proper drainage. The 
left common carotid artery was cannulated using an 18-gauge 
catheter, advancing to the aortic arch.
Full heparinization (500 IU/kg) was ensured after surgical 
preparation and immediately before cardiopulmonary bypass and 
CPA initiation to reduce overall blood loss. The setup consisted 
of a venous reservoir, a roller pump, a hollow fiber oxygenator 
(Sorin, Mirandola, Italy), and a vacuum regulator with an 
applied pressure of −30 mm H2O to facilitate venous drainage, 
all connected by a 1.6-mm internal diameter plastic tubing. Total 
priming volume was 10.5 ml, and gas exchange surface and heat 
exchange surface were of 450 cm2 and 15.8 cm2, respectively.
Experimental Design
In this study, the rats were randomized into two groups (A and 
B): Group A was treated with FTY720 at a dose of 1 mg/kg 
intravenously and Group B with normal saline. After 15 min of 
both treatments, rats from both groups underwent CPA using 
cold St. Thomas solution and aortic clamps for 30 min after 
initiation of extra corporeal life support (ECLS) for the next 
2 h, as described in a previous study (Rungatscher et al., 2013). 
During ECLS, internal temperature was kept at 36–37°C in both 
groups. After 2 h of reperfusion, ECLS weaning was done in all 
rats, and blood and tissue were harvested for further analysis. A 
schematic review of the experiment is illustrated in Figure 1.
Hemodynamics
Hemodynamic parameters were measured at baseline and after 
ECLS weaning using a 2-Fr microtip pressure–volume (P-V) 
conductance catheter (SPR-838, Millar Instruments, Houston, 
TX) inserted into the right carotid artery and advanced into the 
left ventricle. Signals were recorded at a sampling rate of 1,000 
samples using a P-V conductance system (MPVS-400, Millar 
Instruments), stored and displayed on a personal computer by the 
PowerLab Chart 5 Software System (AD Instruments, Colorado 
FIGURE 1 | Schematic view of experimental design.
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Springs, CO). Hemodynamics were measured by recording the 
left ventricular end-systolic (LVESP) and end-diastolic (LVEDP) 
pressures, along with contractility index measuring dP/dt min 
and dP/dt max (Rungatscher et al., 2015).
Serum Inflammatory Markers Analysis
The levels of inflammatory mediators, tumour necrosis factor 
(TNF)-α, interleukin (IL)-6, intercellular adhesion molecule 
(ICAM)-1, and IL-1β (Thermo Scientific, Rockford, IL), were 
determined by enzyme-linked immunosorbent assay (ELISA) kits 
according to the manufacturer’s instructions (Ahmed et al., 2017).
Evaluation of Nitro-Oxidative Stress
To investigate malondialdehyde (MDA) levels in myocardial 
tissue, samples were processed as described by Ohkawa et  al. 
(1979). After centrifugation, supernatant (0.5 ml) reacts with 
thiobarbituric acid (TBA) (0.67%) (1 ml) using another 0.5 ml of 
trichloroacetic acid (TCA) (20%). The myocardial tissue samples 
were incubated at 37°C for 15 min in a water bath and then allowed 
to cool. The color compound obtained from the supernatant 
was extracted using n-butanol, and separation was done by 
centrifugation at 3,000 rpm for 15 min. Absorbance was measured 
at 532 nm (Jenway 6305 UV/visible spectrophotometer). The 
MDA levels in the hearts were expressed in nmol/g of myocardial 
tissue (Ohkawa et al., 1979).
The analysis of reactive oxygen species (ROS) was performed 
with a photometric analytical system as explained by Rizzo 
et al. (2008). This procedure measures the ROS that reacts with 
a particular chromogen, leading to the formation of a colored 
compound in the presence of a buffered solution. This compound 
can be measured photometrically (absorbance peak at 505 nm 
maximum). The determined absorbance value is expressed as 
Carr. units (1 U. Carr = 0.08 mg/100 ml H2O2) (Rizzo et al., 2008).
To assess nitrogen ROS, peroxynitrites were analyzed by 
measuring the nitrosylation of cardiac proteins using an antibody 
against nitrotyrosine by immunohistochemistry using a protocol 
described previously (Ahmed et al., 2017).
Immunoblotting Analysis
The chemical reagents and SDS-PAGE apparatus were obtained 
from Bio-Rad (Hercules, CA). The apparatus for immunoblotting 
was purchased from SciePlas (Southam, England). The rabbit 
antibodies for phospho-specific Akt1/2 and ERK1/2 goat anti-
rabbit IgG conjugated with horseradish peroxidase (HRP) were 
purchased from Abcam (Cambridge, MA). The rabbit anti-
phosphorylated Akt1/2 and ERK1/2 antibodies were purchased 
from Cell Signaling (Beverly, MA). The remaining reagents were 
purchased from Sigma Chemical (St. Louis, MO).
The myocardial tissue was homogenized in buffer solution 
containing 1% Triton with phosphatase and protease inhibitors 
cocktail from Sigma Chemical, as described by Giani et al. (2007). 
Tissue extracts were centrifuged at 16,000 rpm for 15 min at 4°C, 
and supernatants were collected in separate aliquots. Protein 
concentration in the extract was determined by using the BCA 
assay kits (Beyotime Institute of Biotechnology, China) according 
to the manufacturer’s instructions and vector analysis. To assess 
phosphorylation levels of Akt1/2 and ERK1/2, equal amounts of 
solubilized proteins (35 μg) were denatured by boiling for 5 min 
at 100°C in reducing buffer, resolved by SDS-PAGE. The resolved 
proteins were transferred to polyvinylidenedifluoride (PVDF) 
membranes, pre-wetted with methanol and distilled water, 
before submersion in 30% methanol containing transfer buffer. 
After transfer, membranes were incubated for 1 h in blocking 
solution (5% fetal bovine serum in TBS containing 0.1% Tween 
20), followed by incubation with primary antibodies (1:1,000 in 
blocking solution) overnight at 4°C with both unphosphorylated 
and phospho-specific antibodies. Equal loading of protein in the 
acrylamide gels was confirmed by reusing the PVDF membranes 
with antibody against an anti-glyceraldehyde-3-phosphate 
dehydrogenase (anti-GAPDH). After overnight incubation in 
primary antibody, membranes were washed generously with 
TBS-Tween 20 solution for 20 min. Washed membranes were 
incubated with secondary HRP-conjugated antibodies at a 
dilution of 1:10,000, and HRP-substrate chemiluminescence was 
used through Syngene Western blotting detection system. The 
quantification of protein band densities was analyzed by ImageJ 
1.37 software (Giani et al., 2007).
Immunohistochemical Staining
Myocardial tissue sections (3 microns thick) on polarized slides 
were heated to 60°C for 1 h and rehydrated for 20 min with 
xylene and graded ethanol solution. Antigen retrieval was done 
with 0.01 M citrate buffer at pH 6.0 for 30 min in a water bath. 
Gradual cooling was allowed for the next 15 min, followed 
by sequential rinsing with tap water and phosphate buffered 
solution (PBS). Endogenous peroxidase activity was suppressed 
by TBS-T solution with 3% hydrogen peroxide incubation. All 
sections were incubated overnight at 4°C in primary antibodies, 
Bax (Abcam, Cambridge, United Kingdom), Bcl-2 (Dako, Glostrup, 
Denmark), and nitrotyrosine (Sigma Aldrich, United Kingdom). 
After thorough washing of primary antibodies, the slides were 
incubated with biotin-conjugated secondary antibody for 30 
min and di-amino benzidine and hydrogen peroxide chromogen 
substrate (Dako Corp). All slides were counterstained with 
hematoxylin and mounted. The negative controls were incubated 
with non-immune rabbit IgG. Tissue sections from each animal 
were imaged using a light microscope Nikon E400 (Nikon 
Instrument Group, Melville, NY) (Ahmed et al., 2017).
Bcl-2 and Bax Expression Measurement 
Using Real Time-Polymerase Chain 
Reaction
The RNA extraction was done from myocardial tissue and was assessed 
for quality and concentration. cDNA was generated from RNA by 
reverse transcription kit, according to manufacturer’s guidelines. 
The Bcl-2, Bax, and GAPDH (housekeeping gene) primers 
(Table 1) were used to determine the mRNA expression by real-
time fluorescence-based quantitative PCR. Conditions followed 
for this were at 94°C for 5 min, then 45 cycles at 94°C for 30 
s, 57°C for 30 s, 75°C for 30 s, and finally 72°C for 5 min Data 
were exported to MS Excel sheet for further analysis. Relative 
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quantification was calculated using the 2–ΔCt model, where ΔCt 
(Target gene) = CT (Target gene) – CT (Ref. gene) (Li et al., 2018).
High-Energy Phosphates Measurement
The high-energy phosphates estimation includes the determination 
of adenosine nucleotides, that is, adenosine monophosphate 
(AMP), adenosine diphosphate (ADP), adenosine triphosphate 
(ATP), and phosphocreatine (PCr). Myocardial tissue was clamped 
from the beating heart in the chest using liquid nitrogen precooled 
clamps. The frozen ball of myocardial tissue was stored at −80°C 
until extract preparation. Collected heart tissue was submerged 
in liquid nitrogen, and frozen tissue was weighed (50–100 mg) 
and deproteinized by homogenization using 500 µl of 0.4 mol/L 
perchloric acid in a ball mill (Braun, Melsungen, Germany). The 
150 µl of the acid extract was centrifuged at 12,000 G, followed 
by neutralization with 2 mol/L potassium carbonate at 4°C. The 
potassium carbonate was centrifuged, and the supernatant was 
stored at −28°C till further use.
Chromatographic separation was performed on a Hypersil 
ODS column (5 μm, 250 mm long × 4 mm ID) with an AS-100 
HRLC automatic sampling system (Bio-Rad), a 127 HPLC 
solvent module, and a diode array detector module (Beckman). 
Detector signals (absorbance at 214 nm for PCr and 254 nm 
for adenine dinucleotide) were recorded with an AGC personal 
computer. System Gold (Beckman) was used as controller for 
data requisition and analysis. The extract pellets were dissolved 
in 1 ml of 0.1 mol/L sodium hydroxide and further diluted 1:10 
with physiological saline for protein determination (BCA Protein 
Assay, Pierce) (Hallstrom et al., 2002).
Statistical Analysis
Data analysis was done using SPSS software version 21 (SPSS Inc., 
Chicago, Illinois) in all the treatment and control groups. Mean ± SD 
was calculated for all the measurements and appropriate statistical 
tests, that is, Student t test or Mann–Whitney nonparametric tests, 
were applied to compare the two groups. A p value less than 0.05 
was considered statistically significant.
RESULTS
Effect of FTY720 on Left Ventricular 
Function
Baseline hemodynamics were similar in both groups (Table 2). No 
significant difference was observed in groups A and B. Hemodynamic 
measurements were done to evaluate LV performance using the 
Millar catheter system in both groups at baseline and after 2 h of 
reperfusion (Figure 2).
The LVESP was improved after 2 h but statistically did not reach 
the level of significance (p = 0.06). The LVEDP measurements 
showed a reduction after 2 h of reperfusion in the treated versus 
control group (p = 0.03). Ventricular systolic performance dP/
dt max after CPB was improved in the FTY720-treated versus 
control group but did not reach statistical significance (p = 0.2). 
On the other hand, the minimal pressure relaxation rate (dP/dt 
min) was significantly low in control versus treated group (p = 
0.02) (Figure 2).
Serum Levels of Inflammatory Mediators
Inflammatory mediators have been described to contribute in the 
CPA–reperfusion-related I/R injury (Suleiman et al., 2011). In 
the present study, serum levels of a few important inflammatory 
mediators were measured. Although ICAM-1 is independently 
increased in response to I/R, in CPA-related I/R, an increase has 
been observed. In comparison to baseline, TNF-α, IL-6, IL-1β, 
and ICAM-1 serum levels were significantly high in the CPA–
reperfusion group (p ≤ 0.001). On administration of FTY720 
(1 mg/kg), TNF-α, IL-6, 1L-1β, and ICAM-1 (vs. control group) 
were attenuated (p ≤ 0.001, p = 0.04, p = 0.01, and p = 0.001), 
respectively, as shown in (Figure 3).
Nitro-Oxidative Stress
To examine the role of FTY720 in the regulation of free radical 
production inI/R, we quantified free radicals and aldehydes 
(lipid peroxidation derivatives) in perfused frozen myocardial 
samples. In the CPA control group, ROS and MDA levels 
were higher than those in the CPA-FTY720-treated group. 
Collectively, our results suggest that FTY720 treatment in CPA 
decreases oxidative stress (Figures 4A, B). Also, treatment with 
FTY720 resulted in markedly reduced nitrotyrosine protein 
content, indicative of reduced peroxynitrite generation (Figures 
4C, D).
Effect of FTY720 on Erk1/2 and Akt1/2 
Signaling Pathways
Activation of prosurvival signaling pathways (MEK/ERK and 
PI3K/Akt) was analyzed by measuring the phosphorylation status 
of ERK1/2 and Akt on Western blots. As shown in Figures 5A, B 
the phosphorylation levels of ERK1/2 and Akt were increased 
TABLE 1 | RT-PCR primer sequences.







RT-PCR, Real Time-Polymerase Chain Reaction.






HR/min 370 326 Ns*
MAP mmHg 130 129 Ns
LVESP mmHg 95.2 92.2 Ns
LVEDP mmHg 8.2 8.0 Ns
dP/dt max mmHg/s 7,305 7,427 Ns
dP/dt min mmHg/s 7,672 7,511 Ns
*Ns denotes not significant.
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in the treated group compared to those in the controls (p ≤ 0.001 
and p = 0.04, respectively) (n = 15 each).
Bcl-2 and Bax Signaling Pathways
After 30 min of CPA and 2 h of reperfusion, heart tissue was 
removed for immunohistological staining to measure the 
expression of antiapoptotic protein Bcl-2 and its regulator Bax 
protein. As depicted in Figures 6A−D, in the FTY720-treated 
groups, Bcl-2 expression was significantly increased whereas 
in the CPA-related I/R group, the expression of Bax was 
downregulated (p = 0.02) but Bcl-2 was upregulated compared 
to those in Group A. These results indicate that FTY720 during 
global I/R attenuates apoptosis by upregulation of Bcl-2 and 
downregulation of Bax proteins.
Bcl-2 and Bax mRNA Expression Levels
Treatment with FTY720 in the CPA model significantly 
enhanced the mRNA expression of Bcl-2 and reduced the levels 
of Bax protein. There was a marked difference in control group 
as compared to sham group for both proteins. This effect was 
encountered by fingolimod treatment by decreasing Bax and 
increasing Bcl-2 levels to limit apoptosis (Figure 7).
High-Energy Phosphates
The measurement of high-energy phosphates in the model 
of CPA revealed the better preservation of FTY720-treated 
myocardium (Figures 8A−C). The AMP levels were similar 
to control and baseline, but ADP and ATP was significantly 
raised after 2 h of reperfusion in the treated group as compared 
to control group (p < 0.05, p < 0.01, respectively). PCr, the 
buffering energy source that can be utilized during energy 
demand in the form of ATP, was significantly higher in the 
FTY720-administered group compared with that in the control 
group tissue (p < 0.01) (Figure 8D).
FTY720 Attenuates Neutrophil Infiltration
In CPA-related I/R, development of interstitial edema, structural 
disarray, and neutrophil infiltration were observed. However, pre-
ischemia FTY720 treatment remarkably reduced morphological 
changes and neutrophil infiltration, as shown in Figure 9.
FIGURE 2 | Hemodynamic parameters measured at baseline and 2 h after reperfusion. Effects of FTY720 on left ventricular function in the rats with CPA-
reperfusion-induced injury. Treatment (FTY720 or saline) was done 15 min before cardioplegic arrest. (A) Effects of FTY720 on LVESP. (B) Effects of FTY720 on 
LVEDP. (C) Effects of FTY720 on LV dP/dt max. (D) Effects of FTY720 on LV dP/dt min. LVESP and LVEDP were measured using a multichannel physiological 
recorder. LV dP/dt max and dP/dt min were expressed as mmHg/s. LVESP and LVEDP were expressed as mmHg. LV dP/dt max, rate of maximum positive left 
ventricular pressure development; LV dP/dt max, rate of maximum negative left ventricular pressure development; LVESP, left ventricular end-systolic pressure; 
LVEDP, left ventricular end-diastolic pressure. Values are expressed as the means ± SD (n = 15 in each group). #p ≤ 0.01 vs. baseline. *p ≤ 0.05 vs. CPA-control 
group. NS, not significant.
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FIGURE 3 | Myocardial production of TNF-α (A), IL-6 (B), ICAM-1 (C), and IL-1β (D). (A) CPA model without FTY720 treatment shows a high expression of TNF-α 
as compared to FTY720 treatment. (B) CPA-reperfusion induced significantly high ICAM-1 after 2 h of reperfusion compared with the FTY720-treated and baseline. 
(C) FTY720 treatment remarkably reduced the production of ICAM-1 as compared to control. (D) This section of the panel presents the production of 1L-1β, which 
was higher in the control versusthat in the FTY720-treated group. Each bar height represents the mean ± SD (each group n = 15). #p ≤ 0.05 and ##p ≤ 0.01 versus 
baseline. *p ≤ 0.05 and **p ≤ 0.01 versus CPA-control group.
FIGURE 4 | Oxidative stress. Comparison of oxidative and nitrosative stress in FTY720-treated and control group in cardiopulmonary bypass model with CPA (A 
and B). ROS, reactive oxygen species; Carr. unit, Carratelli unit. **p ≤ 0.001, *p ≤ 0.05. Myocardial nitrotyrosine staining (C) FTY720-treated group, (D) control group 
(n = 15). Rats were subjected to 30 min CPA followed by 2 h reperfusion. Yellow arrows indicate nitrotyrosine expression.
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FIGURE 5 | Representative Western blot and relative density ratio of the phosphorylated (p) form of Akt1/2 (A) and ERK1/2 (B), samples of left ventricle at the 
2-h reperfusion. Relative densities show that FTY720 activates phosphorylation of these proteins. Values are means ± SD; n = 15 samples/group. *p ≤ 0.05, **p ≤ 
0.001.
FIGURE 6 | The protein expression levels of Bcl-2 and Bax in myocardial tissue were determined by immunohistochemistry. (A) Bax expression in CPA-control 
group. (B) Bax expression in CPA-FTY720-treated group (control vs. treated, p ≤ 0.05). (C) Bcl-2 expression in the control-CPA group and (D) Bcl-2 expression in 
the FTY720-treated group (control vs. treated, p ≤ 0.01).
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DISCUSSION
This study is the first of its kind to investigate the cardioprotective 
role of FTY720 in a clinically relevant experimental model of 
cardiopulmonary bypass and CPA, mimicking cardiac surgery 
settings. The pharmacological cardioprotective strategy to 
prevent acute global I/R injury has been tested using different 
approaches. Over the last few years, multiple pharmacological 
agents, including volatile anesthetic agents. During last decade, 
different drugs including (Kato and Foex, 2002; Symons and 
Myles, 2006; Yu and Beattie, 2006), sodium hydrogen exchange 
inhibitors (Avkiran and Marber, 2002), statins (Lee et al., 1995; 
Pan et al., 2004; Belhomme et al., 2000), and anti-inflammatory 
drugs have been investigated as a potential myocardial protective 
therapies. However, the majority of preclinical strategies showing 
cardioprotective effects did not show any promising results in 
clinical settings (Jones et al., 2015).
In this study, administration of FTY720 demonstrated reduced 
apoptosis by inhibiting inflammation and oxidative stress. Our 
data show myocardial preservation at both molecular and protein 
levels. We have also demonstrated the activation of survival 
signaling pathways, in addition to inhibition of proapoptotic 
antibodies and activation of antiapoptotic proteins. Akt1/2 and 
Erk1/2 phosphorylation are important for cell survival pathways, 
also investigated in this study (Brewster et al., 2012; Bader et al., 
2014; Yu et al., 2015).
Previous studies had suggested the cardioprotective role of 
FTY720 by activating survival pathways in in vitro and ex vivo 
FIGURE 7 | RT-PCR measurement of Bax and Bcl-2 mRNA expression in myocardial tissue showing the FTY720 effect. (A) Bcl-2 mRNA expression. (B) Bax mRNA 
expression. **p < 0.01 versus the control group; ##p < 0.01 versus the model group and #p < 0.05.
FIGURE 8 | High-energy phosphates in the myocardial tissue of the LV in the FTY720-treated groups compared with those in the control group. (A, B, C) AMP, 
ADP, and ATP levels after 2 h of reperfusion in CPA. (D) Changes in PCr. *p ≤ 0.05, **p ≤ 0.001. AMP, adenosine monophosphate; ADP, adenosine diphosphate; 
ATP, adenosine triphosphate; PCr, phosphocreatine.
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models of mouse and rat hearts and in vivo animal models 
(Jin  et al., 2002; Lecour et al., 2002). Recently, a study has 
reported that knockout mice of S1P receptors produced a high 
level of myocardial damage as compared to wild type (Means 
et al., 2007). Means et al. (Means et al., 2007) showed that mice 
lacking sphingosine kinases were found to have a large infarction 
size compared to control mice. In addition to activation of 
S1P receptors, the metabolism of S1P showed significance 
in preconditioning and postconditioning cardioprotective 
mechanisms (Lecour et al., 2002; Jin et al., 2004; Jin et al., 2007; 
Gomez et al., 2011).
I/R injury can be caused by various mechanisms and 
pathways. Activation of apoptotic pathways, complement system 
activation, increased inflammation, and oxidative stress can 
cause myocardial injury after I/R (Aletras et al., 2006). FTY720 
shows a potential to deal efficiently with most of the myocardial 
damaging mechanisms and prevent I/R injury.
According to literature, S1P receptor agonists have an 
important role in immune suppression (Luessi et al., 2015). 
Various experimental models have been used to test for including 
a porcine model of I/R (Santos-Gallego et al., 2016) and 
spontaneous obstructive coronary atherosclerosis murine model 
(Xu et al., 2014). Using these models, a reduction in infarct 
size and low mortality have been shown in the FTY720-treated 
groups. We have measured inflammatory markers in both blood 
and tissue. In blood, we found a significantly low concentration 
of neutrophils, lymphocytes, and proinflammatory cytokines.
The ICAM-1, IL-6, IL-1β, and TNF-α as proinflammatory 
cytokines contribute to the development of inflammatory 
mechanisms (Bonney et al., 2013; Li et al., 2013; Markowski et al., 
2013). A correlation was found between the anti-inflammatory 
effects of FTY720 on cardioprotection. I/R increased ICAM-
1, IL-6, IL-1β, and TNF-α levels in the control group, whereas 
FTY720 treatment decreased the concentrations of these 
cytokines. Therefore, the suppression of inflammatory cytokines 
by FTY720 treatment protects the myocardium from I/R injury 
caused by these proinflammatory cytokines.
One of the main targets of this drug is to mitigate apoptosis in 
I/R. Molecular signaling RISK and SAFE pathways activation has 
been reported during I/R (Lecour et al., 2002; Zhang et al., 2007). 
The RISK (Akt1/2, Erk1/2, and GSK 3β) and SAFE pathways 
(JAK and STAT3) are the main sources for the mitigation of 
apoptosis to prevent the opening of the mPTP (Heusch et  al., 
2011; Heusch, 2013; Heusch, 2015). Consistent with previous 
findings, activation of RISK and SAFE signaling pathways was 
observed after a decreased level of apoptosis in the treated group 
as compared to that in the control. The decreased activation of 
proapoptotic proteins Bax and enhanced immunoreaction for 
antiapoptotic protein Bcl-2 was observed after 30 min of CPA 
and 2 h of reperfusion. Reperfusion after transient ischemia in 
the myocardial tissue leads to cardiac apoptosis and reduced 
myocardial function (Khan et al., 2006; Oh et al., 2013). That shows 
the protective effect of role of FTY720 by reducing inflammatory 
mediators and oxidative stress. Considering the outcome of our 
study, we believe that the investigation of S1P receptor activation 
in patients undergoing CPA during cardiac surgery will be helpful 
to assess the potential clinical efficacy of this cardioprotective role.
LIMITATIONS
According to literature, coronary artery disease will be the most 
common cardiovascular disease having highest mortality rate 
by 2020 in the entire world by 2020 (Yellon and Baxter, 2000). 
Although with advances in percutaneous techniques, majority 
of the patients undergo percutaneous coronary intervention 
(PCI) but coronary artery bypass grafting ( CABG) remains the 
mainstay of treatment in complex coronary artery disease and/
or valvular disease. Coronary artery disease patients undergoing 
cardiac surgery mostly have associated comorbidities, including 
diabetes, hypertension, and hyperlipidemia, whereas in our 
experimental model, it was not all truly reflected.
In our study, reperfusion time was 2 h, and we could not study 
the effect of FTY720 in late phase. Prolonged reperfusion may 
give more strong evidence of reduction in I/R injury. The effect of 
FTY720 in structural remodeling can be studied only if we could 
increase our reperfusion time but because of the complexity of 
surgery, it is hard to practice.
FIGURE 9 | Representative photomicrograph showing the histopathological changes in rats’ myocardium related to CPA-induced ischemia-reperfusion (20X 
magnification). (A) The cardiac section shows interstitial edema and neutrophil infiltration in the control group of CPA rat model. (B) Heart tissue section showing 
reduced edema and neutrophil infiltration in the FTY720-treated group. Yellow arrows indicate neutrophil infiltration, and blue indicates interstitial edema.
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Furthermore, this study did not assessed the capability of 
FTY720 to enhance myocardial salvage with multiple doses of 
FTY720 or its chronic use because we administered a single dose 
before initiating ischemia in our model.
CONCLUSION
In conclusion, FTY720 preserves high-energy phosphates 
and cardiac mechanical function, as well as attenuation of 
myocardial apoptosis, inflammation, and oxidative stress. 
Furthermore, a cardioprotective mechanism is associated 
with phosphorylation of Akt1/2 and Erk1/2 prosurvival cell 
signaling pathways to prevent myocardial damage. Moreover, 
the question whether a lower dose will have protective effects 
on the myocardium in humans needs to be answered in 
further studies. Future studies of prolonged reperfusion with 
pre-ischemia and post-ischemia and treatment with FTY720 
may give better results and enable the analysis of the effect on 
myocardial remodeling.
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